Madrigal Pharmaceuticals (MDGL)
(Delayed Data from NSDQ)
$338.91 USD
+26.80 (8.59%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $335.58 -3.33 (-0.98%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
MDGL 338.91 +26.80(8.59%)
Will MDGL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MDGL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MDGL
Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates
MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights
MDGL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Madrigal (MDGL) Moves 10.9% Higher: Will This Strength Last?
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
Madrigal (MDGL) Reports Q1 Loss, Tops Revenue Estimates
Other News for MDGL
Madrigal Pharmaceuticals (MDGL) Reports Strong Q2 Revenue Boost
Madrigal Pharmaceuticals reports Q2 EPS ($1.90), consensus ($3.53)
Madrigal Pharmaceuticals, Inc. GAAP EPS of -$1.90 beats by $1.51, revenue of $212.8M beats by $50.63M
Madrigal Pharmaceuticals Inc (MDGL) Reports Strong Q2 2025 Financial Results and Strategic ...